Danielle Ternyila

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.

Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.